Comparison of cytogenetic damage in groups of patients with myeloproliferative neoplasms, depending on the presence or absence of V617F mutation in JAK2 gene
- Авторлар: Kolubaeva S.N1, Polyakov A.S1, Kissel A.V1, Myakoshina L.A1, Viktorova N.A1, Ushanov S.S1, Titova A.A1, Ivanov A.M1, Noskov Y.A1, Bologov S.G1, Voronin S.V1
-
Мекемелер:
- S.M. Kirov Military Medical Academy
- Шығарылым: Том 11, № 3 (2016)
- Беттер: 150-152
- Бөлім: Articles
- ##submission.dateSubmitted##: 05.01.2023
- ##submission.datePublished##: 15.09.2016
- URL: https://genescells.ru/2313-1829/article/view/120616
- DOI: https://doi.org/10.23868/gc120616
- ID: 120616
Дәйексөз келтіру
Аннотация
Толық мәтін
Авторлар туралы
S. Kolubaeva
S.M. Kirov Military Medical AcademySaint Petersburg, Russia
A. Polyakov
S.M. Kirov Military Medical AcademySaint Petersburg, Russia
A. Kissel
S.M. Kirov Military Medical AcademySaint Petersburg, Russia
L. Myakoshina
S.M. Kirov Military Medical AcademySaint Petersburg, Russia
N. Viktorova
S.M. Kirov Military Medical AcademySaint Petersburg, Russia
S. Ushanov
S.M. Kirov Military Medical AcademySaint Petersburg, Russia
A. Titova
S.M. Kirov Military Medical AcademySaint Petersburg, Russia
A. Ivanov
S.M. Kirov Military Medical AcademySaint Petersburg, Russia
Ya. Noskov
S.M. Kirov Military Medical AcademySaint Petersburg, Russia
S. Bologov
S.M. Kirov Military Medical AcademySaint Petersburg, Russia
S. Voronin
S.M. Kirov Military Medical AcademySaint Petersburg, Russia
Әдебиет тізімі
- Tefferi A., Vardiman J.W. Classification and of myeloproliferative neoplasms: Tye 2008 World Health Organization criteria and point of care diagnostic algotryms. Leukemia 2008; 22: 14-22.
- Heim S., Mitelman F. Chronic myeloproliferative neoplasms. In: Cancer Cytogenetics, third edition. Canada: Wiley-Blackwell; 2009; p. 209-32.
- Kaushansky K. The chronic myeloproliferative disorders and mutation of JAK2: Damesh ek's 54 year old speculation comes of age. Best Pract. Res. Clin. Haematol. 2007; 20: 5-12.
- Scott L.M., Tong W., Levine R.L. et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N. Engl. J. Med. 2007; 356: 459-68.
- Nussenzveig R.H., Swierczek S.I., Jelinek J. et al. Polycythemia vera is not initiated by JAK V617F mutation. Exp. Hematol. 2007; 35: 32-8.
- Theocharides A., Boissinot M., Girodon F. et al. Leukemic blasts in transformed JAK2V617F-positive myeloproliferative disorders are frequently negative for the JAK2V617F mutation. Blood 2007; 110: 375-79.
- Pietra D., Li S., Brisci A. et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2007; 111: 1686-89.
- Eds. L. Shaffer, N. Tommerup. An international system for human cytogenetic nomenclature. In: Recommendations of International Standing Commitee on Human Cytogenetic Nomenclature. Basel: S. Karger; 2013.